The Payer’s 2025 Guide to GLP-1 Drugs
Posted on February 13, 2025
Manage Pharmacy Benefits for GLP-1 Drugs
GLP-1 drugs are a hot topic not only in pharmacy but in U.S. culture and business. Forecasts have shown that by 2030 the GLP-1 category will reach $100 billion or higher, and GLP-1 users in the U.S. could number 30 million (approximately 9% of the population).
The unprecedented demand for GLP-1 medications presents both opportunities and challenges for healthcare payers. As utilization continues to grow and new products enter the market, understanding the market and implementing comprehensive management strategies will be crucial for balancing member access with financial sustainability.
In this guide for payers, we share the latest on the GLP-1 drug landscape, covering:
- Payer considerations and strategies
- Data on adherence and health care cost savings
- Shortages and compounding
- Expanded indications
- Public/Consumer perspectives
- And more!
Whether managing GLP-1 drugs for diabetes, obesity, or other indications, download this guide to equip your organization for success!
Also, make sure to visit our GLP-1 Resources Hub for more GLP-1-related information, including a companion paper to The Payer’s 2025 Guide to GLP-1 Drugs.
